schliessen

Filtern

 

Bibliotheken

Angiotensin receptor blocker therapy and risk of cancer

INTRODUCTION: Angiotensin receptor blockers (ARBs) are commonly used antihypertensive medication with several other additional proven benefits. Recent controversy on association of lung cancer and other solid malignancy with the use of ARBs is concerning, although the follow-up studies have shown no... Full description

Journal Title: Journal of Hypertension 2013, Vol.31(8), pp.1532-1534
Main Author: Teo, K., Koon
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 0263-6352 ; DOI: 10.1097/HJH.0b013e328362b7fa
Link: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004872-201308000-00006
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: ovid00004872-201308000-00006
title: Angiotensin receptor blocker therapy and risk of cancer
format: Article
creator:
  • Teo, K., Koon
subjects:
  • Medicine
ispartof: Journal of Hypertension, 2013, Vol.31(8), pp.1532-1534
description: INTRODUCTION: Angiotensin receptor blockers (ARBs) are commonly used antihypertensive medication with several other additional proven benefits. Recent controversy on association of lung cancer and other solid malignancy with the use of ARBs is concerning, although the follow-up studies have shown no such association.METHODS: We used data from the Department of Veterans Affairs electronic medical record system and registries to conduct a retrospective cohort study that compared first-time ARB users with nonusers in 1:15 ratio, after balancing for many baseline differences using inverse probability of treatment weights. We conducted time-to-event survival analyses on the weighted cohort.RESULTS: Of the 1 229 902 patients in the analytic cohort, 346 (0.44%) of the 78 075 treated individuals had a newly incident lung cancer and 6577 (0.57%) of 1 151 826 nontreated individuals were diagnosed with lung cancer. On double robust regression, the weighted hazard ratio was 0.74 (0.67-0.83, P 
language:
source:
identifier: ISSN: 0263-6352 ; DOI: 10.1097/HJH.0b013e328362b7fa
fulltext: fulltext
issn:
  • 0263-6352
  • 02636352
url: Link


@attributes
ID925982360
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid00004872-201308000-00006
sourceidovid
recordidTN_ovid00004872-201308000-00006
sourceformatXML
sourcesystemPC
pqid1428517996
display
typearticle
titleAngiotensin receptor blocker therapy and risk of cancer
creatorTeo, K., Koon
ispartofJournal of Hypertension, 2013, Vol.31(8), pp.1532-1534
identifierISSN: 0263-6352 ; DOI: 10.1097/HJH.0b013e328362b7fa
source
subjectMedicine;
descriptionINTRODUCTION: Angiotensin receptor blockers (ARBs) are commonly used antihypertensive medication with several other additional proven benefits. Recent controversy on association of lung cancer and other solid malignancy with the use of ARBs is concerning, although the follow-up studies have shown no such association.METHODS: We used data from the Department of Veterans Affairs electronic medical record system and registries to conduct a retrospective cohort study that compared first-time ARB users with nonusers in 1:15 ratio, after balancing for many baseline differences using inverse probability of treatment weights. We conducted time-to-event survival analyses on the weighted cohort.RESULTS: Of the 1 229 902 patients in the analytic cohort, 346 (0.44%) of the 78 075 treated individuals had a newly incident lung cancer and 6577 (0.57%) of 1 151 826 nontreated individuals were diagnosed with lung cancer. On double robust regression, the weighted hazard ratio was 0.74 (0.67-0.83, P < 0.0001), suggesting a lung cancer reduction effect with ARB use. There was no difference in rates by ARB subtype.CONCLUSION: In this large nationwide cohort of United States Veterans, we found no evidence to support any concern of increased risk of lung cancer among new users of ARBs compared with nonusers. Our findings were consistent with a protective effect of ARBs.
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004872-201308000-00006$$EView_record_at_Wolters_Kluwer_Health_Ovid_Technologies
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutOvid.html$$EView_Wolters_Kluwer_Health,_Lippincott,_Williams_&_Wilkins_Copyright_Statement
search
creatorcontribTeo, K, Koon
titleAngiotensin receptor blocker therapy and risk of cancer
general
010.1097/HJH.0b013e328362b7fa
1© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
2Lippincott Williams & Wilkins - Journals
sourceidovid
recordidovid00004872-201308000-00006
issn
00263-6352
102636352
rsrctypearticle
creationdate2013
addtitleJournal of Hypertension
searchscopeovid
scopeovid
lsr30VSR-Enriched:[doi, subject, eissn, description, pqid]
sort
titleAngiotensin receptor blocker therapy and risk of cancer
authorTeo, K., Koon
creationdate20130800
facets
frbrgroupid8271491207325307235
frbrtype5
creationdate2013
collectionLippincott Williams & Wilkins Journals (Wolters Kluwer Health)
prefilterarticles
rsrctypearticles
creatorcontribTeo, K., Koon
jtitleJournal of Hypertension
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulastTeo
aufirstKoon
auinitmK.
auTeo, K., Koon
atitleAngiotensin receptor blocker therapy and risk of cancer
jtitleJournal of Hypertension
risdate201308
volume31
issue8
spage1532
epage1534
pages1532-1534
issn0263-6352
formatjournal
genrearticle
ristypeJOUR
pub© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
doi10.1097/HJH.0b013e3283621ea3
eissn14735598
date2013-08